JP2022512891A5 - - Google Patents
Info
- Publication number
- JP2022512891A5 JP2022512891A5 JP2021523839A JP2021523839A JP2022512891A5 JP 2022512891 A5 JP2022512891 A5 JP 2022512891A5 JP 2021523839 A JP2021523839 A JP 2021523839A JP 2021523839 A JP2021523839 A JP 2021523839A JP 2022512891 A5 JP2022512891 A5 JP 2022512891A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- sequence number
- car
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752889P | 2018-10-30 | 2018-10-30 | |
| US62/752,889 | 2018-10-30 | ||
| PCT/US2019/058710 WO2020092467A1 (en) | 2018-10-30 | 2019-10-30 | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512891A JP2022512891A (ja) | 2022-02-07 |
| JP2022512891A5 true JP2022512891A5 (https=) | 2022-10-28 |
| JP7548584B2 JP7548584B2 (ja) | 2024-09-10 |
Family
ID=70464551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523839A Active JP7548584B2 (ja) | 2018-10-30 | 2019-10-30 | 抗ｃｄ７９ｂ抗体およびキメラ抗原レセプターおよびそれらの使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12454574B2 (https=) |
| EP (1) | EP3873939A4 (https=) |
| JP (1) | JP7548584B2 (https=) |
| KR (1) | KR20210098454A (https=) |
| CN (1) | CN113227145A (https=) |
| AU (1) | AU2019370276A1 (https=) |
| CA (1) | CA3118337A1 (https=) |
| WO (1) | WO2020092467A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019370276A1 (en) | 2018-10-30 | 2021-06-10 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
| EP4142778A4 (en) * | 2020-04-30 | 2024-06-05 | Board of Regents, The University of Texas System | ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4347650A1 (en) * | 2021-06-01 | 2024-04-10 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-cd79b antibodies |
| CN114891123B (zh) * | 2022-06-09 | 2024-02-09 | 北京美康基免生物科技有限公司 | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 |
| KR20250057777A (ko) | 2022-07-25 | 2025-04-29 | 인테리우스 바이오테라퓨틱스, 인코포레이티드 | 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof) |
| TW202542200A (zh) * | 2022-12-29 | 2025-11-01 | 美商Ｌｔｚ治療股份有限公司 | 抗CD79b抗體及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT699237E (pt) | 1994-03-17 | 2003-07-31 | Merck Patent Gmbh | Fvs de cadeia anti-egfr e anticorpos anti-egfr |
| AU2004272607B2 (en) | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| EP2176295B1 (en) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| CA2896058A1 (en) | 2012-12-24 | 2014-07-03 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| ES2744540T3 (es) * | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anticuerpos anti-CD79b y procedimientos de uso |
| CN113150147A (zh) * | 2015-03-16 | 2021-07-23 | 塞尔德克斯医疗公司 | 抗-met抗体及其使用方法 |
| JP2018510652A (ja) | 2015-03-18 | 2018-04-19 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体 |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017120280A1 (en) * | 2016-01-06 | 2017-07-13 | Virginia Tech Intellectual Properties, Inc. | Antigen targeting to porcine langerin |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| EP3635099A4 (en) | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
| EP4039274A1 (en) | 2017-07-28 | 2022-08-10 | Phanes Therapeutics, Inc. | Anti-tim-3 antibodies and uses thereof |
| KR20200073203A (ko) | 2017-08-11 | 2020-06-23 | 블링크 바이오메디컬 에스아에스 | 면역조절인자로서의 ｃｄ96-결합제 |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CN109265565B (zh) | 2018-10-10 | 2021-06-01 | 苏州大学 | 一种携带分子开关的抗CD79b嵌合抗原受体及其修饰的免疫细胞和应用 |
| AU2019370276A1 (en) | 2018-10-30 | 2021-06-10 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
-
2019
- 2019-10-30 AU AU2019370276A patent/AU2019370276A1/en active Pending
- 2019-10-30 CN CN201980085366.4A patent/CN113227145A/zh active Pending
- 2019-10-30 WO PCT/US2019/058710 patent/WO2020092467A1/en not_active Ceased
- 2019-10-30 JP JP2021523839A patent/JP7548584B2/ja active Active
- 2019-10-30 CA CA3118337A patent/CA3118337A1/en active Pending
- 2019-10-30 EP EP19878006.6A patent/EP3873939A4/en active Pending
- 2019-10-30 US US17/309,144 patent/US12454574B2/en active Active
- 2019-10-30 KR KR1020217016410A patent/KR20210098454A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512891A5 (https=) | ||
| CA2987118C (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| JP2019523630A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| IL312224B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US20200157224A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
| JP2023539501A5 (https=) | ||
| EP4047018A1 (en) | Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2024539630A5 (https=) | ||
| JP2024543043A5 (https=) | ||
| WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| US20240101701A1 (en) | Antibody-derived t cell activating technologies | |
| AU2018262648B2 (en) | Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis | |
| CN116063512B (zh) | 多功能重组抗体及其制备方法和应用 | |
| EP4724573A1 (en) | Her2 chimeric antigen receptor secreting | |
| Shuptrine et al. | Bifunctional antibodies: preclinical and clinical applications | |
| CN118546255A (zh) | 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用 | |
| CN121591904A (zh) | 靶向Trop2和HER2的双特异性抗体及其制备方法与应用 | |
| JP2023513800A5 (https=) |